Real Time Touch

new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)

Real Time Touch

Cell Signaling Technology Inc patents

Recent patent applications related to Cell Signaling Technology Inc. Cell Signaling Technology Inc is listed as an Agent/Assignee. Note: Cell Signaling Technology Inc may have other listings under different names/spellings. We're not affiliated with Cell Signaling Technology Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Cell Signaling Technology Inc-related inventors

Methods of treating lung cancer by administration of an alk inhibitor

Novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of anaplastic lymphoma kinase (alk) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. Non-small cell lung carcinoma (nsclc). ... Cell Signaling Technology Inc

Method for predicting the response to her2-directed therapy

This invention provides methods for determining or predicting response to her2-directed therapy in an individual.. . ... Cell Signaling Technology Inc

Production of motif-specific and context-independent antibodies using peptide libraries as antigens

A method is provided for producing motif-specific, context-independent antibodies that recognize a plurality of peptides or proteins within a genome that contain the same post-translationally modified motif. The method includes the step of immunizing a host with a degenerate peptide library antigen featuring (i) a fixed target motif containing one or more invariant amino acids including at least one modified amino acid, and (ii) a plurality of degenerate amino acids flanking the motif. ... Cell Signaling Technology Inc

Alk and ros kinase in cancer

The invention provides a method for identifying a patient with cancer or suspected of having cancer as a patient likely to respond to an alk- and/or ros-inhibiting therapeutic, comprising: contacting a biological sample from a patient with a first reagent that specifically binds a polypeptide having ros kinase activity and a second reagent that specifically binds to a polypeptide having alk knase activity, and detecting whether the first reagent or the second reagent specifically binds to the biological sample, wherein detection of binding of either the first reagent or the second reagent to the biological sample identifies the patient as a patient likely to respond to an alk-inhibiting and/or ros-inhibiting therapeutic.. . ... Cell Signaling Technology Inc

Multi component detection

The disclosure provides methods for detecting the concurrent presence of at least two targets within a biological sample. The method includes contacting said biological sample with a first binding agent, said first binding agent operably linked to a first sortase molecule, wherein said first binding agent specifically binds to a first target; contacting said biological sample with a second binding agent, said second binding agent operably linked to a first sortase recognition sequence peptide, wherein said second binding agent specifically binds to a second target; adding a sortase substrate under conditions where a first sortase-mediated ligation of the sortase substrate to the first sortase recognition sequence will produce a ligation product, and detecting the ligation product wherein detection of said ligation product indicates the concurrent presence of the first target and the second target in the biological sample. ... Cell Signaling Technology Inc

Mass spectrometry analysis of mutant polypeptides in biological samples

The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partner into the elution solution; subjecting a portion of the elution solution to liquid chromatography to segregate a plurality of molecules in the portion of the elution solution to obtain sorted molecules; determining the measured accurate mass of at least one sorted molecule present in the elution solution; and determining the presence of the at least one distinct polypeptide in the biological sample when a measured accurate mass of at least one molecule is substantially equal to the predetermined peptide measured accurate mass.. . ... Cell Signaling Technology Inc

Mutant ros expression in human cancer

The invention provides the identification of the presence of mutant ros protein in human cancer. In some embodiments, the mutant ros are fig-ros fusion proteins comprising part of the fig protein fused to the kinase domain of the ros kinase. ... Cell Signaling Technology Inc

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009


This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. is not affiliated or associated with Cell Signaling Technology Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cell Signaling Technology Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by